Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer

Despite recent advances, the treatment of head and neck squamous cell carcinoma (HNSCC) remains an area of high unmet medical need. HNSCC is frequently associated with either amplification or mutational changes in the PI3K pathway, making PI3K an attractive target particularly in cetuximab-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Klinghammer, Konrad, Politz, Oliver, Eder, Theresa, Otto, Raik, Raguse, Jan-Dirk, Albers, Andreas, Kaufmann, Andreas, Tinhofer, Ingeborg, Hoffmann, Jens, Keller, Ulrich, Keilholz, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566806/
https://www.ncbi.nlm.nih.gov/pubmed/33110476
http://dx.doi.org/10.18632/oncotarget.27763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566806/
https://www.ncbi.nlm.nih.gov/pubmed/33110476
http://dx.doi.org/10.18632/oncotarget.27763

Ejemplares similares